Bionpharma is backed by some prominent names in the Pharmaceutical Industry.
Signet Healthcare partners was founded in 1998 with the establishment of the Corporate Opportunities Funds. Since 1998, they have organized three funds and completed investments in approximately 35 companies. The team is comprised of six professionals with principal offices in New York City. This team brings over 100 years’ experience of collective healthcare experience in the specialty pharmaceutical, medical device, private equity and investment banking businesses. For the past sixteen years, Signet Healthcare has maintained its dedicated focus to diversified healthcare investing – primarily serving as lead investor to expansion stage companies engaged in specialty pharmaceuticals, medical devices and the pharma services industries. Read More
Our other strategic partner is Pharmascience Inc. Founded in 1983, Pharmascience is a leading manufacturer of generic drugs in a wide range of therapeutic categories. They are a privately owned company with technologically sophisticated operations designed to satisfy customer expectations for quality products and responsive service . Pharmascience’s R&D laboratory and production facilities are located in Montreal, Quebec and their Canada-wide customer base includes pharmacists, drug wholesalers and major retailers. Pharmacience is the largest pharmaceutical employer in Quebec, Canada, with 1,300 employees and the third largest generic pharmaceutical company in Canada and third largest pharmaceutical company in Canada by number of prescriptions. Pharmascience enjoys a diversified portfolio of over 340 product families, both prescription and OTC with sales in more than 60 countries and is one of the largest providers of generic single-source products. Read more
Athyrium Capital Management LP: Athyrium Capital Management LP is an SEC-registered asset management company formed in 2008 to focus on investment opportunities in the global healthcare sector. Managing funds with over $1.7 billion of committed capital, including a $1.2 billion fund recently closed in May 2015 , Athyrium invests across all healthcare verticals including biopharmaceuticals, medical devices and products, and healthcare services. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes, including private equity, public equity, fixed income, royalties, and other structured securities. The firm's investors include public and corporate pension funds, charitable endowments, insurance companies, funds-of-funds, family offices, university endowments, and sovereign wealth funds. Read more